Table 3 Change in laboratory parameters from double-blind acute phase baseline
Baseline means | Median change (from double-blind acute phase baseline) | ||||||
|---|---|---|---|---|---|---|---|
6-week double-blind N = 122 | 6-month extension N = 120–122 | Current study N = 98–103 | Month 12 (OC) | Month 24 (OC) | |||
n | Median | n | Median | ||||
Total cholesterol, mg/dL | 195.5 | 188.7 | 197.9 | 111 | +5.0 | 54 | −3.0 |
LDL cholesterol, mg/dL | 116.8 | 110.2 | 117.5 | 108 | −4.5 | 53 | −10.0 |
HDL cholesterol, mg/dL | 50.5 | 50.4 | 50.3 | 112 | 1.0 | 54 | −1.0 |
Triglycerides, mg/dL | 151.5 | 151.0 | 157.6 | 111 | +10.0 | 54 | +26.0 |
Glucose, mg/dL | 91.1 | 93.1 | 93.7 | 112 | +2.5 | 54 | +3.5 |
HbA1c, % | 5.3 | 5.3 | 5.4 | 112 | 0.0 | 53 | −0.1 |
Prolactin, ng/mL | 10.9 | 13.1 | 13.7 | 112 | +0.8 | 54 | +0.6 |
Prolactin, males | 10.1 (N = 64) | 9.5 (N = 64) | 8.3 (N = 52) | 59 | −0.2 | 27 | +0.2 |
Prolactin, females | 11.7 (N = 58) | 17.3 (N = 57) | 19.3 (N = 51) | 53 | +1.4 | 27 | +0.6 |